C
CuraSen Therapeutics
Curasen therapeutics, inc
About CuraSen Therapeutics
CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases, including Alzheimer's and Parkinson's, as well as several orphan indications. The company aims to address the growing burden of these diseases on millions of patients and their families, particularly as the population ages. CuraSen operates in the biopharmaceutical market, targeting both common and rare neurodegenerative conditions.
The business model revolves around the discovery and development of novel therapeutic compounds. CuraSen generates revenue through partnerships, licensing agreements, and potentially through the commercialization of its proprietary treatments. The company serves a diverse range of clients, including patients, healthcare providers, and pharmaceutical companies.
Founded in 2018, CuraSen leverages the expertise of its co-founders and team members, who have extensive experience in neuroscience and drug development. The company is driven by a mission to enable patients to
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Oct 2024 | $46M | $183M | Undisclosed | ↗ |
| SERIES AOther financing | Oct 2023 | $18M | $273M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for CuraSen Therapeutics is 2.7K monthly website visits, up 107.7% over the last three months. CuraSen Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
CuraSen Therapeutics in the San Carlos ecosystem
The CuraSen Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Alzheimer's Drug Discovery Foundation
Series A7 investors entered at this stage
New Leaf Venture Partners
Alta Partners- TMTekla Capital Management
Chiesi Ventures
Pappas Capital
Johnson & Johnson Innovation
Longitude Capital
Other known investors1 additional known investor
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CuraSen Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CuraSen Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









